2023-12-02 10:40:00
Since November 8, Novo Nordisk is no longer alone. The Dane will have to deal with competition from the American laboratory Eli Lilly, which has seen its anti-obesity drug approved in the United States. These revolutionary pills – Wegovy from Novo Nordisk, Zepbound from Eli Lilly – from new generations of diabetes treatments have proven their ability to make patients using them lose weight, opening up a gigantic potential market for them. As a result, the stock price of Novo Nordisk has soared by 58% in one year and that of Eli Lilly has soared by 90% since the beginning of March.
1701514672
#antiobesity #pill #war
